Founder & Chief Executive Officer
Sam Shrivastava is the Founder and Chief Executive Officer of Asha Therapeutics. He is the Chairman of the Board of Directors.
Asha Therapeutics (Asha) is a biopharmaceutical company focusing solely on custom chemical design, leveraging the ability of its disruptive PRISM™ technology platform to develop novel therapeutics for neurological and oncological diseases with high unmet medical need. Each compound in Asha Therapeutics’ pipeline is designed to restore cellular health at a pivotal juncture of neuronal downturn.
Under Sam’s leadership, Asha has created a robust, holistic portfolio of therapeutic assets that treat neurological and oncological disease through the identification of targets that have been validated biologically but that until recently had been widely considered undruggable.
Sam obtained his M.S. in Technology from East Tennessee State University and Bachelor’s degree in Mechanical Engineering from National Institute of Technology in Kurukshetra, India. Sam is a graduate of the High-Impact Cancer Research postgraduate certificate program at Harvard Medical School.